Plain-English translation of NCT07267026 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a new medication called in healthy adult volunteers. Researchers want to understand how safe the medication is, how the body handles it, and how it works at different dose levels. This is the first time is being tested in people.
is being developed to treat certain kidney diseases, specifically focal segmental glomerulosclerosis and minimal change disease. Before the medication can be tested in patients with these conditions, researchers need to make sure it is safe and tolerable in healthy people first.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
The study has three parts. In Part 1, you will receive a single dose of the medication (or placebo) at gradually increasing dose levels to see how your body tolerates it. In Part 2, you will take the medication (or placebo) multiple times over several days at doses determined from Part 1 results. In Part 3, you will take a single dose with and without food to see how food affects how your body absorbs the medication. You will have blood tests, vital sign checks, and medical evaluations throughout the study to monitor your safety.
AI-generated summary from trial data ยท Sep 18, 2026 ยท Not medical advice
Australia
Phase
Safety & dosing
Sponsor
Consun Pharmaceutical Group
Enrollment target
~84 participants
Started
December 2025
Primary completion
April 2027
Age range
18 Years โ 55 Years
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary โ some teams are faster than others.
Central contact
Yingying Song, Master
Consun Pharmaceutical Group
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first โ no email needed to get started.